Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma.

J Allergy Clin Immunol Glob · 2026 · PMC12874570 · PMID 41660046

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Our data show a decreasing trend in ICS dosage pre- to post-mepolizumab initiation, including a significant 28% reduction in the proportion of patients with ≥1 medium-dose ICS dispensings.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.